eligibility_summary
Eligible: On ongoing ocrelizumab in specified parent trials without local access, first dose ≥5 months after last parent dose, negative urine pregnancy test if of childbearing potential. Exclude: drug commercially available or via PTAP, prior permanent discontinuation, safety-risk conditions, concurrent therapeutic trials, immunocompromised, active/monitored malignancy, other neurological disorders.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ocrelizumab (RO4964913), a humanized IgG1 monoclonal antibody against CD20. Mechanism: selectively depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis. Consequences: reduces B‑cell antigen presentation, proinflammatory cytokines, and autoantibody production, dampening B–T cell interactions and CNS inflammatory activity in MS. Targets: pre‑B to mature CD20+ B lymphocytes (sparing plasma cells and hematopoietic stem cells). Pathways: B‑cell–mediated adaptive immunity and downstream neuroinflammatory cascades. Trial: open-label, single-arm Phase 3 extension to provide continued ocrelizumab access and assess patient-reported physical impact, safety, and tolerability.